McKenzie Kathryn B 4
4 · NEOGENOMICS INC · Filed Dec 23, 2021
Insider Transaction Report
Form 4
McKenzie Kathryn B
Principal Accounting Officer
Transactions
- Sale
Common Stock
2021-12-21$35.00/sh−1,846$64,610→ 11,689 total - Exercise/Conversion
Common Stock
2021-12-22$9.07/sh+5,000$45,350→ 16,689 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-22−5,000→ 20,000 totalExercise: $9.07Exp: 2022-10-18→ Common Stock (5,000 underlying)
Holdings
- 13,894
Stock Option (Right to Buy)
Exercise: $19.60Exp: 2024-03-01→ Common Stock (13,894 underlying) - 35,171
Stock Option (Right to Buy)
Exercise: $53.17Exp: 2028-03-02→ Common Stock (35,171 underlying) - 40,000
Stock Option (Right to Buy)
Exercise: $8.03Exp: 2023-02-26→ Common Stock (40,000 underlying) - 37,514
Stock Option (Right to Buy)
Exercise: $28.33Exp: 2027-03-02→ Common Stock (37,514 underlying)
Footnotes (6)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vested ratably over the first three anniversary dates of the grant date
- [F3]On February 26, 2018, Ms. McKenzie was granted 48,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.
- [F4]On March 1, 2019, Ms. McKenzie was granted 13,894 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F5]On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.
- [F6]On March 2, 2021, Ms. McKenzie was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.